Herbal composition PHY906 and its use in chemotherapy
Inventors
Liu, Shwu-Huey • Jiang, Zaoli • Cheng, Yung-Chi
Assignees
Publication Number
US-12280085-B2
Publication Date
2025-04-22
Expiration Date
2028-02-14
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
This invention provides herbal compositions useful for increasing the therapeutic index of chemotherapeutic compounds. This invention also provides methods useful for improving the quality of life of an individual undergoing chemotherapy. Furthermore, this invention improves the treatment of disease by increasing the therapeutic index of chemotherapy drugs by administering the herbal composition PHY906 to a mammal undergoing such chemotherapy.
Core Innovation
The invention provides herbal compositions that are useful for increasing the therapeutic index of chemotherapeutic compounds. Specifically, these compositions are formulated with an herbal preparation comprising Scutellaria, Glycyrrhiza, Ziziphus, and Paeonia, together with a pharmaceutically acceptable carrier and one or more chemotherapeutic compounds. The compositions can also be administered in methods for treating diseases in mammals by increasing the therapeutic index of chemotherapy drugs such as sorafenib and capecitabine.
A major problem addressed by this invention is the limited efficacy and significant toxicities associated with current chemotherapeutic regimens, particularly for gastrointestinal cancers such as colorectal, liver, and pancreatic cancers. Existing treatments often result in low survival rates, high mortality, and poor quality of life due to the aggressive nature of these cancers, their resistance to chemotherapy, and the adverse side effects of current drugs. There is a recognized unmet need for regimens that increase anticancer effectiveness and reduce side effects.
The invention discloses methods for administering the herbal composition PHY906 in combination with chemotherapeutic agents, resulting in enhanced antitumor activity, reduced toxicity, and improved quality of life for patients undergoing chemotherapy. The herbal composition is shown to potentiate the therapeutic index of cancer chemotherapeutics by not only enhancing antitumor effects but also ameliorating chemotherapy-induced toxicities such as body weight loss and mortality in preclinical animal models.
Claims Coverage
The patent includes one independent claim, focusing on a method for reducing chemotherapy-induced toxicities and increasing anticancer effectiveness through a defined herbal composition in combination with sorafenib.
Combination of sorafenib and a defined herbal composition
The inventive feature is the method of reducing chemotherapy-induced toxicities and increasing anticancer effectiveness of sorafenib in the treatment of cancer by administering to a mammal an anticancer effective amount of sorafenib in combination with a composition comprising an herbal preparation consisting essentially of Scutellaria baicalensis, Glycyrrhiza uralensis, Ziziphus jujuba, and Paeonia lactiflora. The composition is formulated in pharmaceutical dosage form with a pharmaceutically acceptable carrier, additive and/or excipient.
The inventive features claim the combination therapy of sorafenib and a specific herbal composition for improving both efficacy and safety in cancer treatment.
Stated Advantages
The herbal composition reduces chemotherapy-induced toxicities, such as body weight loss and mortality, in mammals undergoing chemotherapy.
The composition enhances the antitumor efficacy of a broad-spectrum of anticancer agents in various cancer models.
The methods improve the therapeutic index of chemotherapy drugs by increasing effectiveness and reducing side effects.
The invention provides methods for improving the quality of life for individuals undergoing chemotherapy.
Documented Applications
Use in combination with chemotherapeutic compounds, particularly sorafenib and capecitabine, for cancer treatment in mammals.
Treatment of gastrointestinal cancers such as colorectal, liver, and pancreatic cancer in mammals, including humans.
Reduction of chemotherapy-induced toxicities and enhancement of antitumor activity in preclinical models of colorectal, liver, and pancreatic cancer.
Relief of side effects and improvement of quality of life in patients undergoing chemotherapy.
Interested in licensing this patent?